Skip to main content
Top
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis

Authors: George Perides, Yuzheng Zhuge, Tina Lin, Monique F Stins, Roderick T Bronson, Julian K Wu

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Patients with metastatic tumors to the brain have a very poor prognosis. Increased metastatic potential has been associated with the fibrinolytic system. We investigated the role of the fibrinolytic enzyme plasmin in tumor cell migration across brain endothelial cells and growth of brain metastases in an experimental metastatic melanoma model.

Methods

Metastatic tumors to the brain were established by direct injection into the striatum or by intracarotid injection of B16F10 mouse melanoma cells in C57Bl mice. The role of plasminogen in the ability of human melanoma cells to cross a human blood-brain barrier model was studied on a transwell system.

Results

Wild type mice treated with the plasmin inhibitor epsilon-aminocaproic acid (EACA) and plg -/- mice developed smaller tumors and survived longer than untreated wild type mice. Tumors metastasized to the brain of wild type mice treated with EACA and plg -/- less efficiently than in untreated wild type mice. No difference was observed in the tumor growth in any of the three groups of mice. Human melanoma cells were able to cross the human blood-brain barrier model in a plasmin dependent manner.

Conclusion

Plasmin facilitates the development of tumor metastasis to the brain. Inhibition of the fibrinolytic system could be considered as means to prevent tumor metastasis to the brain.
Appendix
Available only for authorised users
Literature
1.
go back to reference Levin VA, Sheline GE, Cutin PH: Neoplasms of the central nervous system. Cancer Principles and Practice of Oncology. Edited by: De Vita VTJ, Hellman S and Rosenberg SA. 1993, Philadelphia, J.B. Lippincott Company, 1679-1737. 4th Levin VA, Sheline GE, Cutin PH: Neoplasms of the central nervous system. Cancer Principles and Practice of Oncology. Edited by: De Vita VTJ, Hellman S and Rosenberg SA. 1993, Philadelphia, J.B. Lippincott Company, 1679-1737. 4th
2.
go back to reference Posner JB: Neurologic complications of cancer. 1995, Philadelphia, F.A. Davis Company Posner JB: Neurologic complications of cancer. 1995, Philadelphia, F.A. Davis Company
3.
go back to reference Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol. 1978, 19: 579-591.PubMed Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol. 1978, 19: 579-591.PubMed
4.
go back to reference Sawaya R, Bindal RK: Metastatic brain tumors. Brain tumors. Edited by: Kaye AH and Laws JER. 1995, Edinburgh, Churchill Livingstone, 923-946. Sawaya R, Bindal RK: Metastatic brain tumors. Brain tumors. Edited by: Kaye AH and Laws JER. 1995, Edinburgh, Churchill Livingstone, 923-946.
5.
go back to reference Arbit E, Wronski M: Clinical decision making in brain metastases. Neurosurg Clinics North Am. 1996, 7: 447-457. Arbit E, Wronski M: Clinical decision making in brain metastases. Neurosurg Clinics North Am. 1996, 7: 447-457.
7.
go back to reference Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teichler BA, Reich E, Warren D, Lynch C, Richardson P, Snipper L, Frei E, Antman K: Double dose of intensive chemotherapy with autologous stem cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and caboplatin. J Clin Oncol. 1996, 14: 2984-2992.PubMed Ayash LJ, Elias A, Schwartz G, Wheeler C, Ibrahim J, Teichler BA, Reich E, Warren D, Lynch C, Richardson P, Snipper L, Frei E, Antman K: Double dose of intensive chemotherapy with autologous stem cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and caboplatin. J Clin Oncol. 1996, 14: 2984-2992.PubMed
8.
go back to reference Thorgeirsson UP, Lindsay CK, Cottam DW, Gomez DE: Tumor invasion, proteolysis, and angiogenesis. J Neuro-Oncol. 1994, 18: 89-103. 10.1007/BF01050415.CrossRef Thorgeirsson UP, Lindsay CK, Cottam DW, Gomez DE: Tumor invasion, proteolysis, and angiogenesis. J Neuro-Oncol. 1994, 18: 89-103. 10.1007/BF01050415.CrossRef
9.
go back to reference Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasminogen system. FASEB J. 1995, 9: 939-945.PubMed Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasminogen system. FASEB J. 1995, 9: 939-945.PubMed
11.
go back to reference Sober AJ, Koh HK, Tran NLT, Washington CBJ: Melanoma and other skin cancers. Harrison's Principles of Internal Medicine. Edited by: Fauci AS, Braunwald E, Isselbacher JJ, D. WJ, Martin JB, Kasper DL, Hauser SL and Longo DL. 1998, New York, McGraw-Hill, 543-549. 14th Sober AJ, Koh HK, Tran NLT, Washington CBJ: Melanoma and other skin cancers. Harrison's Principles of Internal Medicine. Edited by: Fauci AS, Braunwald E, Isselbacher JJ, D. WJ, Martin JB, Kasper DL, Hauser SL and Longo DL. 1998, New York, McGraw-Hill, 543-549. 14th
12.
go back to reference Stins MF, Gilles F, Kim KS: Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol. 1997, 76: 81-90. 10.1016/S0165-5728(97)00036-2.CrossRefPubMed Stins MF, Gilles F, Kim KS: Selective expression of adhesion molecules on human brain microvascular endothelial cells. J Neuroimmunol. 1997, 76: 81-90. 10.1016/S0165-5728(97)00036-2.CrossRefPubMed
13.
go back to reference Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M: A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol. 1997, 158: 3499-3510.PubMed Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M: A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol. 1997, 158: 3499-3510.PubMed
14.
go back to reference Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D: Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995, 92: 2585-2593.CrossRefPubMed Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D: Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995, 92: 2585-2593.CrossRefPubMed
15.
go back to reference Schackert G, Fidler IJ: Development of in vivo models for studies of brain metastasis. Int J Cancer. 1988, 41: 589-594.CrossRefPubMed Schackert G, Fidler IJ: Development of in vivo models for studies of brain metastasis. Int J Cancer. 1988, 41: 589-594.CrossRefPubMed
16.
go back to reference Hughes WL, Commerford SL, Gitlin D, Krueger RC, Schultze B, Shah V, Reilly P: Deoxyribonucleic acid metabolism in vivo: cell proliferation and death as measured by incorporation and elimination of iododeoxyuridine. Fed Proc. 1964, 23: 640-648.PubMed Hughes WL, Commerford SL, Gitlin D, Krueger RC, Schultze B, Shah V, Reilly P: Deoxyribonucleic acid metabolism in vivo: cell proliferation and death as measured by incorporation and elimination of iododeoxyuridine. Fed Proc. 1964, 23: 640-648.PubMed
17.
go back to reference Schackert G, Price JE, Bucana CD, Fidler IJ: Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int J Cancer. 1989, 44: 892-897.CrossRefPubMed Schackert G, Price JE, Bucana CD, Fidler IJ: Unique patterns of brain metastasis produced by different human carcinomas in athymic nude mice. Int J Cancer. 1989, 44: 892-897.CrossRefPubMed
18.
go back to reference Sawaya R, Mandybur T, Ormsby I, Tew JMJ: Antifibrinolytic therapy of experimentally grown malignant brain tumors. J Neurosurg. 1989, 64: 263-268.CrossRef Sawaya R, Mandybur T, Ormsby I, Tew JMJ: Antifibrinolytic therapy of experimentally grown malignant brain tumors. J Neurosurg. 1989, 64: 263-268.CrossRef
19.
go back to reference Brockway WJ, Castellino FJ: The mechanism of the inhibition of plasmin activity by e-aminocaproic acid. The Journal of Biological Chemistry. 1971, 246: 4641-4647. Brockway WJ, Castellino FJ: The mechanism of the inhibition of plasmin activity by e-aminocaproic acid. The Journal of Biological Chemistry. 1971, 246: 4641-4647.
20.
go back to reference Stins MF, Prasadarao NV, Zhou J, Arditi M, Kim KS: Bovine brain microvascular endothelial cells transfected with SV40-large T antigen: development of an immortalized cell line to study pathophysiology of CNS disease. In Vitro Cell Dev Biol Anim. 1997, 33: 243-247.CrossRefPubMed Stins MF, Prasadarao NV, Zhou J, Arditi M, Kim KS: Bovine brain microvascular endothelial cells transfected with SV40-large T antigen: development of an immortalized cell line to study pathophysiology of CNS disease. In Vitro Cell Dev Biol Anim. 1997, 33: 243-247.CrossRefPubMed
21.
go back to reference Butler WB, Kirkland WL, Jorgensen TL: Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). Biochemical & Biophysical Research Communications. 1979, 90: 1328-1334.CrossRef Butler WB, Kirkland WL, Jorgensen TL: Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). Biochemical & Biophysical Research Communications. 1979, 90: 1328-1334.CrossRef
22.
go back to reference Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermontt E, Fennelly JJ, O'Higgins N: Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme & Protein. 1996, 49: 85-93. Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermontt E, Fennelly JJ, O'Higgins N: Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme & Protein. 1996, 49: 85-93.
23.
go back to reference Ronne E, Hoyer-Hansen G, Brunner N, Pedersen H, Rank F, Osborne CK, Clark GM, Dano K, Grondahl-Hansen J: Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treatm. 1995, 33: 199-207. 10.1007/BF00665944.CrossRef Ronne E, Hoyer-Hansen G, Brunner N, Pedersen H, Rank F, Osborne CK, Clark GM, Dano K, Grondahl-Hansen J: Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treatm. 1995, 33: 199-207. 10.1007/BF00665944.CrossRef
24.
go back to reference Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L, Graeff H: Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler. 1992, 373: 611-622.CrossRefPubMed Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L, Graeff H: Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler. 1992, 373: 611-622.CrossRefPubMed
25.
go back to reference Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano K, Degen JL: Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene. 1998, 16: 3097-3104. 10.1038/sj.onc.1201869.CrossRefPubMed Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano K, Degen JL: Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene. 1998, 16: 3097-3104. 10.1038/sj.onc.1201869.CrossRefPubMed
26.
go back to reference Praus M, Wauterickx K, Collen D, Gerard RD: Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther. 1999, 6: 227-236. 10.1038/sj.gt.3300802.CrossRefPubMed Praus M, Wauterickx K, Collen D, Gerard RD: Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Ther. 1999, 6: 227-236. 10.1038/sj.gt.3300802.CrossRefPubMed
27.
go back to reference Praus M, Collen D, Gerard RD: Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer. 2002, 102: 584-591. 10.1002/ijc.10767.CrossRefPubMed Praus M, Collen D, Gerard RD: Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis. Int J Cancer. 2002, 102: 584-591. 10.1002/ijc.10767.CrossRefPubMed
28.
go back to reference Szende B, Okada Y, Tsuda Y, Horvath A, Bokonyi G, Okamoto S, Wanaka K, Keri G: A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. In Vivo. 2002, 16: 281-286.PubMed Szende B, Okada Y, Tsuda Y, Horvath A, Bokonyi G, Okamoto S, Wanaka K, Keri G: A novel plasmin-inhibitor inhibits the growth of human tumor xenografts and decreases metastasis number. In Vivo. 2002, 16: 281-286.PubMed
29.
go back to reference Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). International Journal of Cancer. 1995, 63: 840-845.CrossRefPubMed Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP: Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). International Journal of Cancer. 1995, 63: 840-845.CrossRefPubMed
30.
go back to reference Xing RH, Rabbani SA: Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. International Journal of Cancer. 1996, 67: 423-429. 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8.CrossRefPubMed Xing RH, Rabbani SA: Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. International Journal of Cancer. 1996, 67: 423-429. 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8.CrossRefPubMed
31.
go back to reference Stetler-Stevenson WG: Progelatinase A activation during tumor cell invasion. Invasion Metastasis. 1994, 14: 259-268.PubMed Stetler-Stevenson WG: Progelatinase A activation during tumor cell invasion. Invasion Metastasis. 1994, 14: 259-268.PubMed
32.
go back to reference Maguire T, Chin D, Souta D, Duffy MJ: Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. International Journal of Cancer. 2000, 85: 457-459. 10.1002/(SICI)1097-0215(20000215)85:4<457::AID-IJC2>3.0.CO;2-6.CrossRefPubMed Maguire T, Chin D, Souta D, Duffy MJ: Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin. International Journal of Cancer. 2000, 85: 457-459. 10.1002/(SICI)1097-0215(20000215)85:4<457::AID-IJC2>3.0.CO;2-6.CrossRefPubMed
33.
go back to reference Stahl A, Mueller BM: Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. International Journal of Cancer. 1997, 71: 116-122. 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.0.CO;2-G.CrossRefPubMed Stahl A, Mueller BM: Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. International Journal of Cancer. 1997, 71: 116-122. 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.0.CO;2-G.CrossRefPubMed
34.
go back to reference Ignar DM, Andrews JL, Witherspoon SM, Leray JD, Clay WC, Kilpatrick K, Onori J, Kost T, Emerson DL: Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis. 1998, 16: 9-20. 10.1023/A:1006503816792.CrossRefPubMed Ignar DM, Andrews JL, Witherspoon SM, Leray JD, Clay WC, Kilpatrick K, Onori J, Kost T, Emerson DL: Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis. 1998, 16: 9-20. 10.1023/A:1006503816792.CrossRefPubMed
35.
go back to reference Ma D, Gerard RD, Li XY, Alizadeh H, Niederkorn JY: Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood. 1997, 90: 2738-2746.PubMed Ma D, Gerard RD, Li XY, Alizadeh H, Niederkorn JY: Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood. 1997, 90: 2738-2746.PubMed
36.
go back to reference Gundersen D, Tran-Thang C, Sordat B, Mourali F, Ruegg C: Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J Immunol. 1997, 158: 1051-1060.PubMed Gundersen D, Tran-Thang C, Sordat B, Mourali F, Ruegg C: Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J Immunol. 1997, 158: 1051-1060.PubMed
37.
go back to reference Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest. 1997, 100: 58-67.CrossRefPubMedPubMedCentral Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest. 1997, 100: 58-67.CrossRefPubMedPubMedCentral
38.
go back to reference Barilla ML, Carsons SE: Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum. 2000, 29: 252-265. 10.1016/S0049-0172(00)80012-8.CrossRefPubMed Barilla ML, Carsons SE: Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum. 2000, 29: 252-265. 10.1016/S0049-0172(00)80012-8.CrossRefPubMed
39.
go back to reference Chen ZL, Strickland S: Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997, 91: 917-925. 10.1016/S0092-8674(00)80483-3.CrossRefPubMed Chen ZL, Strickland S: Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell. 1997, 91: 917-925. 10.1016/S0092-8674(00)80483-3.CrossRefPubMed
40.
go back to reference Silletti S, Mei F, Sheppard D, Montgomery AM: Plasmin-sensitive dibasic sequences in the third fibronectin-like domain of L1-cell adhesion molecule (CAM) facilitate homomultimerization and concomitant integrin recruitment. J Cell Biol. 2000, 149: 1485-1502. 10.1083/jcb.149.7.1485.CrossRefPubMedPubMedCentral Silletti S, Mei F, Sheppard D, Montgomery AM: Plasmin-sensitive dibasic sequences in the third fibronectin-like domain of L1-cell adhesion molecule (CAM) facilitate homomultimerization and concomitant integrin recruitment. J Cell Biol. 2000, 149: 1485-1502. 10.1083/jcb.149.7.1485.CrossRefPubMedPubMedCentral
41.
go back to reference Cairns RA, Khokha R, Hill RP: Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med. 2003, 3: 659-671. 10.2174/1566524033479447.CrossRefPubMed Cairns RA, Khokha R, Hill RP: Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med. 2003, 3: 659-671. 10.2174/1566524033479447.CrossRefPubMed
42.
go back to reference Arnold SM, Young AB, Munn RK, Patchell RA, Nanayakkara N, Markesbery WR: Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin Cancer Res. 1999, 5: 4028-4033.PubMed Arnold SM, Young AB, Munn RK, Patchell RA, Nanayakkara N, Markesbery WR: Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin Cancer Res. 1999, 5: 4028-4033.PubMed
43.
go back to reference Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H, Matsuura N: Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004, 64: 4190-4196. 10.1158/0008-5472.CAN-03-3235.CrossRefPubMed Shintani Y, Higashiyama S, Ohta M, Hirabayashi H, Yamamoto S, Yoshimasu T, Matsuda H, Matsuura N: Overexpression of ADAM9 in non-small cell lung cancer correlates with brain metastasis. Cancer Res. 2004, 64: 4190-4196. 10.1158/0008-5472.CAN-03-3235.CrossRefPubMed
44.
go back to reference Gijbels K, Galardy RE, Steinman L: Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. Journal of Clinical Investigation. 1994, 94: 2177-2182.CrossRefPubMedPubMedCentral Gijbels K, Galardy RE, Steinman L: Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. Journal of Clinical Investigation. 1994, 94: 2177-2182.CrossRefPubMedPubMedCentral
Metadata
Title
The fibrinolytic system facilitates tumor cell migration across the blood-brain barrier in experimental melanoma brain metastasis
Authors
George Perides
Yuzheng Zhuge
Tina Lin
Monique F Stins
Roderick T Bronson
Julian K Wu
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-56

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine